Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials

BACKGROUND: Tumor necrosis factor-α (TNF-α) antibodies are currently used in patients with moderate to severe Crohn’s disease (CD) who are unresponsive to conventional therapies. Certolizumab pegol (Cp) is one of the anti-TNF-α agents introduced for the management of CD and rheumatoid arthritis. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikfar, Shekoufeh, Ehteshami-Afshar, Solmaz, Abdollahi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918190/
https://www.ncbi.nlm.nih.gov/pubmed/24578833
http://dx.doi.org/10.5812/ircmj.11258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918190/
https://www.ncbi.nlm.nih.gov/pubmed/24578833
http://dx.doi.org/10.5812/ircmj.11258

Ejemplares similares